To assess the diagnostic yield of targeted prostate biopsy in African-American (A-A) men using image fusion of multiparametric magnetic resonance imaging (mpMRI) with realtime transrectal ultrasonography (US).
Introduction
In the USA, African-American (A-A) men have the highest incidence of prostate cancer compared to any other racial or ethnic group [1] . It is also well-documented that A-A men with prostate cancer more frequently present with higher grade tumours. However, it is unclear whether this difference is due to lower access to screening or other socioeconomic and education variables that prevent early diagnosis, or if tumours within the A-A population tend to be more biologically aggressive [2] .
Recently, increasing evidence supports the use of MRI with ultrasonography (US) image-fusion targeted prostate biopsy to improve the detection of aggressive prostate cancers, while limiting detection of indolent cancers compared to conventional systematic random biopsy [3] [4] [5] [6] .
In the present study, we compared outcomes of multiparametric (mp)MRI and real-time TRUS imagefusion targeted biopsy (FTB) in A-A men with Caucasian men.
To our best of knowledge, the present study is the first to focus on the diagnostic yield of targeted prostate biopsy using image fusion of mpMRI with real-time TRUS in A-A men.
Patients and Methods
After verification from the Institutional Review Board, we retrospectively reviewed 762 patients who underwent pre-biopsy 3-T mpMRI and subsequent MRI/US FTB between October 2012 and August 2015. A flow diagram of the number of patients who were suitable for study inclusion is presented in Figure 1 . All patients underwent pre-biopsy mpMRI and MRI/US FTB sampling was performed if the mpMRI results were abnormal. After excluding patients in whom the mpMRI did not identify any lesions or those who had previous interventions, 117 A-A men were included and compared with 544 Caucasian men.
The mpMRIs were performed using 3-T clinical MRI instruments and reported on a 5-point Likert scale of suspicion [7] (Table 1) . Three-dimensional volume data from mpMRI and real-time TRUS images were visualised on the screen of a computer workstation, the UroStation (Koelis, Grenoble, France) [6, 8] . All of the MRI/US FTBs and simultaneous conventional random biopsies were taken at Chesapeake Urology Associates (Owings Mills, MD, USA) and data were analysed at the USC Institute of Urology, Keck School of Medicine, University of Southern California (Los Angeles, CA, USA). A standard random biopsy was taken with conventional systematic 10-12 cores per patient and MRI/US FTB was performed with ≥1 core/lesion.
The definition for clinically significant prostate cancer (CSPC) was set at a Gleason score of ≥3+4 in this study.
Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS â version 23; IBM Corporation, Armonk, NY, USA) software. Statistically significant differences were assessed using the Mann-Whitney U-test for continuous data and the chi-square test for categorical data. After controlling for age, pre-biopsy PSA level and estimated prostate volume using multivariable logistic regression modelling, we statistically compared overall cancer and CSPC detection rates between A-A and Caucasian men. The results were considered statistically significant at P < 0.05.
Results
The characteristics of the 661 patients, including 117 A-A and 544 Caucasian men, are shown in Table 2 . The median age of A-A men was 1.5 years younger than the Caucasian men (63.0 vs 64.5 years, P = 0.003). There were no significant differences between the two cohorts for median pre-biopsy PSA level (7.1 vs 6.9 ng/ml, P = 0.274), estimated prostate volume (52.9 vs 51.9 mL, P = 0.585) and number of lesions on MRI per patient (2.0 vs 2.0, P = 0.878). The study population included the spectrum of men offered prostate biopsy, including i) biopsy na€ ıve men with a clinical suspicion of prostate cancer based on increased PSA level and/or abnormal DRE, ii) men with previous negative biopsy with persistent clinical suspicion of prostate cancer based on increased PSA level and/or abnormal DRE, and iii) men with histologically confirmed cancer on an active surveillance protocol or previous atypical cells. However, there was no statistically difference in the proportion of reasons for biopsy between the two races (P = 0.134).
For conventional random biopsy, there were no significant differences between the A-A and Caucasian men in the detection rates of overall cancer (37.2% vs 42.9%, P = 0.294) and CSPC (12.4% vs 15.9%, P = 0.728) ( Table 3) .
On the pre-biopsy mpMRI, the proportion of the dominant lesion on the 5-point Likert scale scoring was not statistically different between the two races (Table 4) . Table 5 (A) shows the overall cancer detection rates in the dominant lesions with MRI/US FTB. There were no significant differences in the overall cancer detection rates for the grade 1-2 (lower suspicion) lesions (14.0% vs 18.5%, P = 0.429) and the grade 4-5 (higher suspicion) lesions (70.6% vs 69.6%, P = 0.934) between A-A and Caucasian men, respectively. However, the cancer detection rate for the grade 3 (equivocal suspicion) lesions in A-A men was significantly higher than that in Caucasian men (47.6% vs 28.9%, P = 0.019). Table 5 (B) shows the CSPC detection rates in the dominant lesions with MRI/US FTB. There were no differences in any of the scoring groups between A-A and Caucasian men.
After controlling for age, pre-biopsy PSA level and prostate volume, there were no significant differences between A-A and Caucasian men in the detection rate of overall In A-A men, MRI/US FTB from the grade 4-5 lesions outperformed random biopsy and MRI/US FTB from the grade 1-3 lesions in the detection rate of overall cancer (70.6% vs 37.2% vs 28.3%, P = 0.003) and CSPC (52.9% vs 12.4% vs 12.1%, P < 0.001), respectively.
For the location of dominant lesions on mpMRI, there were no significant differences between A-A and Caucasian men [ Table 6 (A)]. Table 6 (B and C) shows the detection rates of overall cancer and CSPC in the peripheral zone (PZ) and transition zone (TZ) with MRI/US FTB. There were no significant differences between A-A and Caucasian men, as well as between the PZ and TZ. Table 7 shows the comparison between conventional random biopsy and MRI/US FTB for the dominant lesions in A-A men. A higher proportion of cores were positive for any cancers using MRI/US FTB than random biopsy (24.9% vs 6.8%, P < 0.001). The median cancer core length with MRI/ US FTB was significantly greater than that of random biopsy (4.97 vs 2.39 mm, P < 0.001). In addition, the mean number of cores needed to detect one patient with any cancer was 27.3 and 7.15 for random biopsy and MRI/US FTB, respectively (P < 0.001). The mean number of cores needed to detect one patient with CSPC was 81.9 and 13.3 for random biopsy and MRI/US FTB, respectively (P < 0.001).
Discussion
To our knowledge, the present study is the first to focus on the diagnostic yield of targeted prostate biopsy in A-A men using image fusion of mpMRI with real-time TRUS.
Our key finding is that MRI/US FTB detected more CSPC in A-A men using fewer cores compared with conventional random biopsy; and also, at the time of diagnosis of prostate cancer using MRI/US FTB, there were statistically no differences in the detection rates of prostate cancer between A-A and Caucasian men.
After controlling for age, pre-biopsy PSA level and estimated prostate volume, there were no statistically significant differences in the overall cancer and CSPC detection rates between the races. Recently, mpMRI has been increasingly used in patients with a high suspicion of prostate cancer and MRI/US FTB may replace the more traditional TRUS-guided biopsy in the future [9] . Interestingly, however, our present study showed that the overall cancer detection rate only for the grade 3 (equivocal suspicion) lesions in A-A men was significantly higher than in Caucasian men (47.6% vs 28.9%, P = 0.019). However, there were no differences in the CSPC detection rate for the grade 3 lesions between the two races. Taken together, this may imply that the grade 3 lesions in A-A men have a tendency to contain more clinically insignificant prostate cancer compared to Caucasian men. Further investigations will be needed to clarify this issue.
In general, prostate cancer remains the most common malignancy and the second leading cause of cancer death among men in the USA [10] . In addition, it has previously been reported that prostate cancer exhibits the most striking racial difference, as A-A men are at a 1.4-times higher risk of being diagnosed and at 2-3-times higher risk of dying from prostate cancer, compared to Caucasian men [2, 11, 12] . Furthermore, A-A men present at a more advanced disease stage, are administered different treatment regimens, and have shorter progression-free survival after treatment [2, [13] [14] [15] . It is known that prostate cancer racial difference exists at stages of presentation, diagnosis, treatment regimens and subsequent survival, and quality of life. The difference is complex involving biological, socioeconomic and sociocultural determinants [2, [16] [17] [18] [19] .
The biological contribution to prostate cancer difference in A-A vs Caucasian men is an area of great research interest. Devaney et al. [20] recently reported that genome-wide methylation patterns differed by ethnic/racial groups, which suggests distinct differences in the aetiology of prostate cancer in A-A vs Caucasian men. It has also been reported that A-A men more often estimated their likelihood of prostate cancer as 0% at biopsy, despite higher risk. Reasons for these low estimates and their potential contribution to poor treatment outcomes of A-A patients require further investigation [21] .
On the other hand, in a large population-based study of patients with low-risk low-volume prostate cancer, it was reported that A-A men were no more likely to have pathologically aggressive features than Caucasian men [22] . In recent years, A-A men have experienced greater improvement in prostate cancer survival, and the racial difference has decreased [23] .
Taken together, it is still controversial as to whether A-A race is an independent predictor of adverse oncological outcomes in patients with prostate cancer. Therefore, future follow-up data of the present study population may help in identifying answers to this question.
There are several limitations to the present study. First, the present study is retrospective and the study population heterogeneous, comprising of biopsy na€ ıve men, men with prior negative biopsy, and men with prior positive biopsy. Second, the MRIs were reviewed independently by fellowship-trained abdominal radiologists with potentially varying levels of experience in prostate MRI interpretation because of the practical clinical setting of the present study. Third, we used a Likert scale as a reporting system of prostate MRI. Although 5-point Likert scale scoring and Prostate Imaging-Reporting and Data System version 2 (PI-RADS v2) are well-known reporting systems of prostate MRI, controversy still exists on the best way to report [24] [25] [26] . Additionally, our reference standard is based on prostate biopsy rather than the final prostatectomy specimen. Also our present analysis excluded patients without visible lesions on MRI and subsequently the rate of CSPC in such patients has not been assessed. Furthermore, we classified all Gleason ≥7 as CSPC; however, the definition of CSPC is controversial and debatable with no universally accepted definition. Lastly, the extra costs and efforts associated with mpMRI and MRI/US FTB should be further investigated with consideration of possible cost savings due to reductions in repeat biopsies.
Conclusions
The present study is the first to focus on the diagnostic yield of targeted prostate biopsy in A-A men using image fusion of mpMRI with real-time TRUS. Our present findings indicate a lack of different racial outcomes for CSPC detected with MRI/US FTB. Furthermore, we also found that MRI/US FTB detected more CSPC using fewer cores compared with conventional random biopsy, with histological findings correlating with the level of suspicion on mpMRI.
